[2026-07-27] Korea Breaks Ground on ‘Korea Light Source’ — $840M 4th-Gen Accelerator to Power Semiconductor, Battery and Drug R&D

On July 27, 2026, Korea’s Ministry of Science and ICT (MSIT) and the Korea Basic Science Institute (KBSI) held a groundbreaking ceremony for the Korea Light Source (KLS), a 4th-generation storage-ring synchrotron radiation facility, at a dedicated site in Ochang, Cheongju, North Chungcheong Province. The project carries a total budget of KRW 1.1643 trillion (roughly USD 840 million at current exchange rates) and is scheduled for completion by the end of 2029. KBSI leads the construction project, with the Pohang Accelerator Laboratory at POSTECH participating as a co-development institution. In a written congratulatory message, President Lee Jae-myung said he hopes the facility becomes a foundation for Korea’s future growth engines in semiconductors, secondary batteries and advanced materials, as well as a hub for regional innovation-led growth in Cheongju.

What was built, and why it matters

A synchrotron radiation facility accelerates electrons to near light speed to produce extremely bright light, used to analyze the atomic-level structure and properties of materials. The KLS is a 4th-generation, circular (multi-purpose) synchrotron that produces light a trillion times brighter than the sun and achieves over 100 times the efficiency of Korea’s existing 3rd-generation facility, covering a broad energy range of 150–3,000 electron volts (eV). Unlike Korea’s existing linear 4th-generation facility (PAL-XFEL, completed 2017 at Pohang), which is used mainly for ultrafast basic research, the circular design allows multiple simultaneous “beamlines,” making KLS the country’s first facility purpose-built for broad industrial use in semiconductors, secondary batteries, and new drug and vaccine development.

How Korea compares to Japan and the US

Korea’s closest comparison point is Japan’s SPring-8, built between 1991 and 1997 at a total cost of approximately 110 billion yen, jointly operated by RIKEN and JASRI. SPring-8 has anchored synchrotron research across Asian academia and industry for nearly three decades, though it started as a 3rd-generation facility — a generation behind what Korea is now building from scratch. The US took a different path: Argonne National Laboratory upgraded its existing 3rd-generation Advanced Photon Source (APS) through an $815 million project completed in early 2026, aiming to make it the world’s brightest synchrotron X-ray facility. Where the US chose to upgrade an existing facility, Korea chose to build a new 4th-generation circular facility from the ground up, splitting roles with the existing Pohang site (basic research) and the new Ochang site (industrial application).

Why this policy matters for the United States

Korea’s semiconductor and battery manufacturers currently rely in part on booking beamtime at overseas synchrotron facilities, including US and Japanese sites, to analyze advanced materials as process nodes shrink toward 2nm and below. A domestic 4th-generation facility reduces that dependency and accelerates Korean firms’ R&D cycles — firms that sit deep inside US chip and EV battery supply chains as suppliers to companies like Nvidia, Apple, and major US automakers. At the same time, the US comparison point (Argonne’s APS-U) shows Washington pursuing the same brightness target through a different, upgrade-based strategy, underscoring that advanced-materials analysis infrastructure has become a competitive front among allied manufacturing powers, not just a basic-science investment.

Industry and consumer impact

For industry, the facility is expected to shorten R&D cycles for Korea’s HBM and AI-chip supply chain and secondary battery materials sectors by giving them domestic access to atomic-scale structural analysis that previously required overseas beamtime reservations. A separately announced KRW 170 billion Phase-3 clinical trial fund from Korea’s Ministry of Health and Welfare addresses near-term clinical financing, while KLS itself won’t be operational until 2029 — different timelines, but together they point to funding and analysis infrastructure building up in parallel as twin pillars for Korea’s pharmaceutical and biotech sector over the longer run. For consumers, the effects are indirect and long-term: improved chip and battery competitiveness gradually feeds into device and EV pricing and performance, while faster drug development could shorten the time domestic patients wait for access to new treatments — effects likely to play out over a 5-to-10-year horizon rather than immediately.

Source: https://www.korea.kr/news/policyNewsView.do?newsId=148968869